Condition
Melanoma Stage IIIB-IV
Total Trials
3
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 2 (3)
Trial Status
Recruiting2
Unknown1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06624644Phase 2Recruiting
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
NCT06651151Phase 2RecruitingPrimary
NeoLIPA: Neoadjuvant LTX-315 in Combination with Pembrolizumab in Resectable Stage III/IV Melanoma
NCT04248387Phase 2UnknownPrimary
Toripalimab in the Neoadjuvant Treatment of BRAF V600 Wild Type Melanoma
Showing all 3 trials